{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T19:34:59Z","timestamp":1777059299917,"version":"3.51.4"},"publisher-location":"Cham","reference-count":81,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783032228994","type":"print"},{"value":"9783032229007","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/164_2025_786","type":"book-chapter","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T16:56:43Z","timestamp":1767027403000},"page":"99-121","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Direct Oral Anticoagulant Inhibitors: Mode of Action, Clinical Aspects"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0696-6848","authenticated-orcid":false,"given":"Eman","family":"Hassan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Will","family":"Lester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"issue":"1","key":"786_CR1","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1161\/circulationaha.107.709204","volume":"117","author":"W Ageno","year":"2008","unstructured":"Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW (2008) Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 117(1):93\u2013102. https:\/\/doi.org\/10.1161\/circulationaha.107.709204","journal-title":"Circulation"},{"issue":"17","key":"786_CR2","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","volume":"382","author":"G Agnelli","year":"2020","unstructured":"Agnelli G, Becattini C, Meyer G et al (2020) Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 382(17):1599\u20131607. https:\/\/doi.org\/10.1056\/NEJMoa1915103","journal-title":"N Engl J Med"},{"issue":"4","key":"786_CR3","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s11239-022-02705-6","volume":"54","author":"A Albuloushi","year":"2022","unstructured":"Albuloushi A, Rhoten M, Kelly J, Sylvester KW, Grandoni J, Connors JM (2022) Evaluation of the use of direct oral anticoagulants for the management of heparin-induced thrombocytopenia. J Thromb Thrombolysis 54(4):597\u2013604. https:\/\/doi.org\/10.1007\/s11239-022-02705-6","journal-title":"J Thromb Thrombolysis"},{"issue":"6","key":"786_CR4","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1001\/jamacardio.2016.1829","volume":"1","author":"JH Alexander","year":"2016","unstructured":"Alexander JH, Andersson U, Lopes RD et al (2016) Apixaban 5 mg twice daily and clinical outcomes in patients with atrial fibrillation and advanced age, low body weight, or high creatinine: a secondary analysis of a randomized clinical trial. JAMA Cardiol 1(6):673\u2013681. https:\/\/doi.org\/10.1001\/jamacardio.2016.1829","journal-title":"JAMA Cardiol"},{"issue":"7","key":"786_CR5","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1111\/jgs.18372","volume":"71","author":"American Geriatrics Society","year":"2023","unstructured":"American Geriatrics Society (2023) American Geriatrics Society 2023 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults. J Am Geriatr Soc 71(7):2052\u20132081. https:\/\/doi.org\/10.1111\/jgs.18372","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"786_CR6","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1160\/th16-03-0224","volume":"117","author":"JE Ansell","year":"2017","unstructured":"Ansell JE, Bakhru SH, Laulicht BE et al (2017) Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban. Thromb Haemost 117(2):238\u2013245. https:\/\/doi.org\/10.1160\/th16-03-0224","journal-title":"Thromb Haemost"},{"issue":"3","key":"786_CR7","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1053\/j.jvca.2020.10.042","volume":"35","author":"H Apostel","year":"2021","unstructured":"Apostel H, Winckers K, Bidar E, Schreiber JU (2021) Successful antithrombin administration in andexanet alfa-associated heparin resistance. J Cardiothorac Vasc Anesth 35(3):904\u2013907. https:\/\/doi.org\/10.1053\/j.jvca.2020.10.042","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"3","key":"786_CR8","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.117.007338","volume":"7","author":"KN Aronis","year":"2018","unstructured":"Aronis KN, Hylek EM (2018) Evidence gaps in the era of non-vitamin K Oral anticoagulants. J Am Heart Assoc 7(3):e007338. https:\/\/doi.org\/10.1161\/jaha.117.007338","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"786_CR9","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1111\/bjh.19729","volume":"205","author":"P Baker","year":"2024","unstructured":"Baker P, Platton S, Arachchillage DJ, Kitchen S, Patel J, Riat R, Gomez K, Committee tB (2024) Measurement of heparin, direct oral anti-coagulants and other non-coumarin anti-coagulants and their effects on haemostasis assays: a British Society for Haematology Guideline. Br J Haematol 205(4):1302\u20131318. https:\/\/doi.org\/10.1111\/bjh.19729","journal-title":"Br J Haematol"},{"issue":"1","key":"786_CR10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1161\/circulationaha.116.022361","volume":"134","author":"EA Bohula","year":"2016","unstructured":"Bohula EA, Giugliano RP, Ruff CT, Kuder JF, Murphy SA, Antman EM, Braunwald E (2016) Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial. Circulation 134(1):24\u201336. https:\/\/doi.org\/10.1161\/circulationaha.116.022361","journal-title":"Circulation"},{"issue":"9","key":"786_CR11","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1016\/j.jtha.2024.05.023","volume":"22","author":"S Carlin","year":"2024","unstructured":"Carlin S, Cuker A, Gatt A et al (2024) Anticoagulation for stroke prevention in atrial fibrillation and treatment of venous thromboembolism and portal vein thrombosis in cirrhosis: guidance from the SSC of the ISTH. J Thromb Haemost 22(9):2653\u20132669. https:\/\/doi.org\/10.1016\/j.jtha.2024.05.023","journal-title":"J Thromb Haemost"},{"issue":"10","key":"786_CR12","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1161\/atvbaha.123.318781","volume":"43","author":"NC Chan","year":"2023","unstructured":"Chan NC, Weitz JI (2023) New therapeutic targets for the prevention and treatment of venous thromboembolism with a focus on factor XI inhibitors. Arterioscler Thromb Vasc Biol 43(10):1755\u20131763. https:\/\/doi.org\/10.1161\/atvbaha.123.318781","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"13","key":"786_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.120.017559","volume":"9","author":"A Chen","year":"2020","unstructured":"Chen A, Stecker E, Warden BA (2020) Direct Oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc 9(13):e017559. https:\/\/doi.org\/10.1161\/jaha.120.017559","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"786_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.100107","volume":"7","author":"T Chiasakul","year":"2023","unstructured":"Chiasakul T, Crowther M, Cuker A (2023) Four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-associated bleeding: a meta-analysis of fixed versus variable dosing. Res Pract Thromb Haemost 7(2):100107. https:\/\/doi.org\/10.1016\/j.rpth.2023.100107","journal-title":"Res Pract Thromb Haemost"},{"issue":"9","key":"786_CR15","doi-asserted-by":"publisher","first-page":"e426","DOI":"10.1016\/s2352-3026(16)30079-5","volume":"3","author":"H Cohen","year":"2016","unstructured":"Cohen H, Hunt BJ, Efthymiou M et al (2016) Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2\/3, non-inferiority trial. Lancet Haematol 3(9):e426\u2013e436. https:\/\/doi.org\/10.1016\/s2352-3026(16)30079-5","journal-title":"Lancet Haematol"},{"issue":"12","key":"786_CR16","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1177\/0961203320950461","volume":"29","author":"H Cohen","year":"2020","unstructured":"Cohen H, Cuadrado MJ, Erkan D et al (2020) 16th international congress on Antiphospholipid antibodies task force report on Antiphospholipid syndrome treatment trends. Lupus 29(12):1571\u20131593. https:\/\/doi.org\/10.1177\/0961203320950461","journal-title":"Lupus"},{"issue":"3","key":"786_CR17","doi-asserted-by":"publisher","first-page":"426","DOI":"10.3174\/ajnr.A3000","volume":"33","author":"J Comin","year":"2012","unstructured":"Comin J, Kallmes DF (2012) Dabigatran (Pradaxa). AJNR Am J Neuroradiol 33(3):426\u2013428. https:\/\/doi.org\/10.3174\/ajnr.A3000","journal-title":"AJNR Am J Neuroradiol"},{"issue":"14","key":"786_CR18","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","volume":"380","author":"SJ Connolly","year":"2019","unstructured":"Connolly SJ, Crowther M, Eikelboom JW et al (2019) Full study report of Andexanet Alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 380(14):1326\u20131335. https:\/\/doi.org\/10.1056\/NEJMoa1814051","journal-title":"N Engl J Med"},{"issue":"19","key":"786_CR19","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1056\/NEJMoa2313040","volume":"390","author":"SJ Connolly","year":"2024","unstructured":"Connolly SJ, Sharma M, Cohen AT et al (2024) Andexanet for factor Xa inhibitor-associated acute intracerebral hemorrhage. N Engl J Med 390(19):1745\u20131755. https:\/\/doi.org\/10.1056\/NEJMoa2313040","journal-title":"N Engl J Med"},{"issue":"10","key":"786_CR20","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/jama.2024.12708","volume":"332","author":"JD Douketis","year":"2024","unstructured":"Douketis JD, Spyropoulos AC (2024) Perioperative management of patients taking direct oral anticoagulants: a review. JAMA 332(10):825\u2013834. https:\/\/doi.org\/10.1001\/jama.2024.12708","journal-title":"JAMA"},{"issue":"6","key":"786_CR21","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1097\/aap.0000000000000478","volume":"41","author":"J Douketis","year":"2016","unstructured":"Douketis J, Schulman S, Syed S (2016) Reply to Dr Lessire et al. Reg Anesth Pain Med 41(6):788. https:\/\/doi.org\/10.1097\/aap.0000000000000478","journal-title":"Reg Anesth Pain Med"},{"issue":"11","key":"786_CR22","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1001\/jamainternmed.2019.2431","volume":"179","author":"JD Douketis","year":"2019","unstructured":"Douketis JD, Spyropoulos AC, Duncan J et al (2019) Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant. JAMA Intern Med 179(11):1469\u20131478. https:\/\/doi.org\/10.1001\/jamainternmed.2019.2431","journal-title":"JAMA Intern Med"},{"issue":"10","key":"786_CR23","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/j.ajem.2019.01.008","volume":"37","author":"D Dybdahl","year":"2019","unstructured":"Dybdahl D, Walliser G, Chance Spalding M, Pershing M, Kincaid M (2019) Four-factor prothrombin complex concentrate for the reversal of factor Xa inhibitors for traumatic intracranial hemorrhage. Am J Emerg Med 37(10):1907\u20131911. https:\/\/doi.org\/10.1016\/j.ajem.2019.01.008","journal-title":"Am J Emerg Med"},{"key":"786_CR24","unstructured":"EMC (2024a) Xarelto 20mg film-coated tablets. https:\/\/www.medicines.org.uk\/emc\/product\/2793\/smpc#gref. Accessed Dec 2024"},{"key":"786_CR25","unstructured":"EMC (2024b) Lixiana 60mg film-coated tablets. https:\/\/www.medicines.org.uk\/emc\/product\/6905\/smpc#gref. Accessed Dec 2024"},{"issue":"7","key":"786_CR26","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1016\/j.jtha.2023.04.021","volume":"21","author":"JC Fredenburgh","year":"2023","unstructured":"Fredenburgh JC, Weitz JI (2023) News at XI: moving beyond factor Xa inhibitors. J Thromb Haemost 21(7):1692\u20131702. https:\/\/doi.org\/10.1016\/j.jtha.2023.04.021","journal-title":"J Thromb Haemost"},{"issue":"24","key":"786_CR27","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1016\/j.jacc.2021.04.061","volume":"77","author":"A G\u00f3mez-Outes","year":"2021","unstructured":"G\u00f3mez-Outes A, Alcubilla P, Calvo-Rojas G, Terleira-Fern\u00e1ndez AI, Su\u00e1rez-Gea ML, Lecumberri R, Vargas-Castrill\u00f3n E (2021) Meta-analysis of reversal agents for severe bleeding associated with direct Oral anticoagulants. J Am Coll Cardiol 77(24):2987\u20133001. https:\/\/doi.org\/10.1016\/j.jacc.2021.04.061","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"786_CR28","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1016\/s2352-3026(20)30368-9","volume":"8","author":"J Halton","year":"2021","unstructured":"Halton J, Brand\u00e3o LR, Luciani M et al (2021) Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b\/3, non-inferiority trial. Lancet Haematol 8(1):e22\u2013e33. https:\/\/doi.org\/10.1016\/s2352-3026(20)30368-9","journal-title":"Lancet Haematol"},{"key":"786_CR29","doi-asserted-by":"publisher","unstructured":"Harkness W, Pipitone O, Joss J, Schiedler M, Shagavah S, Moore R, Hsing J (2022) Observed Apixaban anti-Xa levels in obese patients. Ann Pharmacother. https:\/\/doi.org\/10.1177\/10600280221077158","DOI":"10.1177\/10600280221077158"},{"issue":"10","key":"786_CR30","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1093\/europace\/euv309","volume":"17","author":"H Heidbuchel","year":"2015","unstructured":"Heidbuchel H, Verhamme P, Alings M et al (2015) Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 17(10):1467\u20131507. https:\/\/doi.org\/10.1093\/europace\/euv309","journal-title":"Europace"},{"issue":"10","key":"786_CR31","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s40265-018-0940-4","volume":"78","author":"YA Heo","year":"2018","unstructured":"Heo YA (2018) Andexanet Alfa: first global approval. Drugs 78(10):1049\u20131055. https:\/\/doi.org\/10.1007\/s40265-018-0940-4","journal-title":"Drugs"},{"issue":"7-8","key":"786_CR32","doi-asserted-by":"publisher","first-page":"707","DOI":"10.23736\/s0375-9393.23.17230-0","volume":"89","author":"L Heubner","year":"2023","unstructured":"Heubner L, Vicent O, Beyer-Westendorf J, Spieth PM (2023) Bleeding management in patients with direct oral anticoagulants. Minerva Anestesiol 89(7-8):707\u2013715. https:\/\/doi.org\/10.23736\/s0375-9393.23.17230-0","journal-title":"Minerva Anestesiol"},{"issue":"1","key":"786_CR33","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","volume":"74","author":"CT January","year":"2019","unstructured":"January CT, Wann LS, Calkins H et al (2019) 2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 74(1):104\u2013132. https:\/\/doi.org\/10.1016\/j.jacc.2019.01.011","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"786_CR34","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1161\/circulationaha.123.066485","volume":"149","author":"LPT Joosten","year":"2024","unstructured":"Joosten LPT, van Doorn S, van de Ven PM et al (2024) Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist Oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomized controlled trial. Circulation 149(4):279\u2013289. https:\/\/doi.org\/10.1161\/circulationaha.123.066485","journal-title":"Circulation"},{"issue":"1","key":"786_CR35","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","volume":"81","author":"CD Khairani","year":"2023","unstructured":"Khairani CD, Bejjani A, Piazza G et al (2023) Direct Oral anticoagulants vs vitamin K antagonists in patients with Antiphospholipid syndromes: meta-analysis of randomized trials. J Am Coll Cardiol 81(1):16\u201330. https:\/\/doi.org\/10.1016\/j.jacc.2022.10.008","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"786_CR36","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1056\/NEJMoa1814630","volume":"380","author":"AA Khorana","year":"2019","unstructured":"Khorana AA, Soff GA, Kakkar AK et al (2019) Rivaroxaban for Thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med 380(8):720\u2013728. https:\/\/doi.org\/10.1056\/NEJMoa1814630","journal-title":"N Engl J Med"},{"issue":"2","key":"786_CR37","doi-asserted-by":"publisher","first-page":"e190","DOI":"10.1055\/s-0038-1649507","volume":"2","author":"PY Kim","year":"2018","unstructured":"Kim PY, Yeh CH, Dale BJ, Leslie BA, Stafford AR, Fredenburgh JC, Hirsh J, Weitz JI (2018) Mechanistic basis for the differential effects of rivaroxaban and Apixaban on global tests of coagulation. TH Open 2(2):e190\u2013e201. https:\/\/doi.org\/10.1055\/s-0038-1649507","journal-title":"TH Open"},{"issue":"11","key":"786_CR38","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1016\/j.jtha.2024.08.006","volume":"22","author":"M Kovac","year":"2024","unstructured":"Kovac M, Ignjatovic V, Orlando C, Bereczky Z, Hunt BJ (2024) The use of direct oral anticoagulants in the secondary prevention of venous thromboembolism in patients with severe thrombophilia: communication from the ISTH SSC Subcommittee on Physiological Anticoagulants and Thrombophilia. J Thromb Haemost 22(11):3322\u20133329. https:\/\/doi.org\/10.1016\/j.jtha.2024.08.006","journal-title":"J Thromb Haemost"},{"issue":"2","key":"786_CR39","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1177\/0091270006296058","volume":"47","author":"D Kubitza","year":"2007","unstructured":"Kubitza D, Becka M, Zuehlsdorf M, Mueck W (2007) Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol 47(2):218\u2013226. https:\/\/doi.org\/10.1177\/0091270006296058","journal-title":"J Clin Pharmacol"},{"issue":"17","key":"786_CR40","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1016\/j.jacc.2019.08.1031","volume":"74","author":"S Kumar","year":"2019","unstructured":"Kumar S, Lim E, Covic A, Verhamme P, Gale CP, Camm AJ, Goldsmith D (2019) Anticoagulation in concomitant chronic kidney disease and atrial fibrillation: JACC review topic of the week. J Am Coll Cardiol 74(17):2204\u20132215. https:\/\/doi.org\/10.1016\/j.jacc.2019.08.1031","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"786_CR41","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/cc12592","volume":"17","author":"A Lazo-Langner","year":"2013","unstructured":"Lazo-Langner A, Lang ES, Douketis J (2013) Clinical review: clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications. Crit Care 17(3):230. https:\/\/doi.org\/10.1186\/cc12592","journal-title":"Crit Care"},{"issue":"9","key":"786_CR42","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1111\/jth.15823","volume":"20","author":"R Leong","year":"2022","unstructured":"Leong R, Chu DK, Crowther MA, Mithoowani S (2022) Direct oral anticoagulants after bariatric surgery-what is the evidence? J Thromb Haemost 20(9):1988\u20132000. https:\/\/doi.org\/10.1111\/jth.15823","journal-title":"J Thromb Haemost"},{"issue":"5","key":"786_CR43","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrcardio.2017.223","volume":"15","author":"JH Levy","year":"2018","unstructured":"Levy JH, Douketis J, Weitz JI (2018) Reversal agents for non-vitamin K antagonist oral anticoagulants. Nat Rev Cardiol 15(5):273\u2013281. https:\/\/doi.org\/10.1038\/nrcardio.2017.223","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"786_CR44","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/s2352-3026(19)30219-4","volume":"7","author":"C Male","year":"2020","unstructured":"Male C, Lensing AWA, Palumbo JS et al (2020) Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol 7(1):e18\u2013e27. https:\/\/doi.org\/10.1016\/s2352-3026(19)30219-4","journal-title":"Lancet Haematol"},{"issue":"8","key":"786_CR45","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1111\/jth.15358","volume":"19","author":"KA Martin","year":"2021","unstructured":"Martin KA, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S (2021) Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC subcommittee on control of anticoagulation. J Thromb Haemost 19(8):1874\u20131882. https:\/\/doi.org\/10.1111\/jth.15358","journal-title":"J Thromb Haemost"},{"key":"786_CR46","doi-asserted-by":"publisher","unstructured":"Martinez BK, Sood NA, Bunz TJ, Coleman CI (2018) Effectiveness and safety of Apixaban, dabigatran, and rivaroxaban versus warfarin in frail patients with Nonvalvular atrial fibrillation. J Am Heart Assoc 7(8). https:\/\/doi.org\/10.1161\/jaha.118.008643","DOI":"10.1161\/jaha.118.008643"},{"issue":"2","key":"786_CR47","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/jth.14662","volume":"18","author":"RD McBane 2nd","year":"2020","unstructured":"McBane RD 2nd, Wysokinski WE, Le-Rademacher JG et al (2020) Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost 18(2):411\u2013421. https:\/\/doi.org\/10.1111\/jth.14662","journal-title":"J Thromb Haemost"},{"issue":"4","key":"786_CR48","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s11239-021-02480-w","volume":"52","author":"I Milioglou","year":"2021","unstructured":"Milioglou I, Farmakis I, Neudeker M, Hussain Z, Guha A, Giannakoulas G, Kotoula V, Papaioannou M (2021) Prothrombin complex concentrate in major bleeding associated with DOACs; an updated systematic review and meta-analysis. J Thromb Thrombolysis 52(4):1137\u20131150. https:\/\/doi.org\/10.1007\/s11239-021-02480-w","journal-title":"J Thromb Thrombolysis"},{"issue":"13","key":"786_CR49","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1161\/circulationaha.121.057844","volume":"147","author":"TJ Milling Jr","year":"2023","unstructured":"Milling TJ Jr, Middeldorp S, Xu L et al (2023) Final study report of Andexanet Alfa for major bleeding with factor Xa inhibitors. Circulation 147(13):1026\u20131038. https:\/\/doi.org\/10.1161\/circulationaha.121.057844","journal-title":"Circulation"},{"issue":"9","key":"786_CR50","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1016\/j.ajem.2020.05.086","volume":"38","author":"TJ Milling","year":"2020","unstructured":"Milling TJ, Pollack CV (2020) A review of guidelines on anticoagulation reversal across different clinical scenarios - is there a general consensus? Am J Emerg Med 38(9):1890\u20131903. https:\/\/doi.org\/10.1016\/j.ajem.2020.05.086","journal-title":"Am J Emerg Med"},{"issue":"10","key":"786_CR51","doi-asserted-by":"publisher","first-page":"685","DOI":"10.7326\/m19-0291","volume":"171","author":"J Ordi-Ros","year":"2019","unstructured":"Ordi-Ros J, S\u00e1ez-Comet L, P\u00e9rez-Conesa M et al (2019) Rivaroxaban versus vitamin K antagonist in Antiphospholipid syndrome: a randomized noninferiority trial. Ann Intern Med 171(10):685\u2013694. https:\/\/doi.org\/10.7326\/m19-0291","journal-title":"Ann Intern Med"},{"issue":"2","key":"786_CR52","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s11239-015-1272-9","volume":"41","author":"S Patel","year":"2016","unstructured":"Patel S, Steen D (2016) Widening the path and window of opportunity for FDA approval of non-vitamin K oral anticoagulant specific antidotes and reversal agents. J Thromb Thrombolysis 41(2):285\u2013292. https:\/\/doi.org\/10.1007\/s11239-015-1272-9","journal-title":"J Thromb Thrombolysis"},{"key":"786_CR53","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ahj.2019.08.002","volume":"217","author":"RM Payne","year":"2019","unstructured":"Payne RM, Burns KM, Glatz AC et al (2019) A multi-national trial of a direct oral anticoagulant in children with cardiac disease: design and rationale of the safety of ApiXaban on pediatric heart disease on the preventioN of embolism (SAXOPHONE) study. Am Heart J 217:52\u201363. https:\/\/doi.org\/10.1016\/j.ahj.2019.08.002","journal-title":"Am Heart J"},{"issue":"13","key":"786_CR54","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","volume":"132","author":"V Pengo","year":"2018","unstructured":"Pengo V, Denas G, Zoppellaro G et al (2018) Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 132(13):1365\u20131371. https:\/\/doi.org\/10.1182\/blood-2018-04-848333","journal-title":"Blood"},{"issue":"2","key":"786_CR55","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/jth.15158","volume":"19","author":"V Pengo","year":"2021","unstructured":"Pengo V, Hoxha A, Andreoli L et al (2021) Trial of rivaroxaban in AntiPhospholipid syndrome (TRAPS): two-year outcomes after the study closure. J Thromb Haemost 19(2):531\u2013535. https:\/\/doi.org\/10.1111\/jth.15158","journal-title":"J Thromb Haemost"},{"key":"786_CR56","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ahj.2019.04.009","volume":"213","author":"LM Pina","year":"2019","unstructured":"Pina LM, Dong X, Zhang L et al (2019) Rivaroxaban, a direct factor Xa inhibitor, versus acetylsalicylic acid as thromboprophylaxis in children post-Fontan procedure: rationale and design of a prospective, randomized trial (the UNIVERSE study). Am Heart J 213:97\u2013104. https:\/\/doi.org\/10.1016\/j.ahj.2019.04.009","journal-title":"Am Heart J"},{"issue":"2","key":"786_CR57","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1182\/bloodadvances.2018024133","volume":"3","author":"S Piran","year":"2019","unstructured":"Piran S, Khatib R, Schulman S, Majeed A, Holbrook A, Witt DM, Wiercioch W, Sch\u00fcnemann HJ, Nieuwlaat R (2019) Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis. Blood Adv 3(2):158\u2013167. https:\/\/doi.org\/10.1182\/bloodadvances.2018024133","journal-title":"Blood Adv"},{"issue":"5","key":"786_CR58","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1056\/NEJMoa1707278","volume":"377","author":"CV Pollack Jr","year":"2017","unstructured":"Pollack CV Jr, Reilly PA, van Ryn J et al (2017) Idarucizumab for dabigatran reversal \u2013 full cohort analysis. N Engl J Med 377(5):431\u2013441. https:\/\/doi.org\/10.1056\/NEJMoa1707278","journal-title":"N Engl J Med"},{"issue":"7","key":"786_CR59","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","volume":"378","author":"GE Raskob","year":"2018","unstructured":"Raskob GE, van Es N, Verhamme P et al (2018) Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 378(7):615\u2013624. https:\/\/doi.org\/10.1056\/NEJMoa1711948","journal-title":"N Engl J Med"},{"issue":"10","key":"786_CR60","doi-asserted-by":"publisher","first-page":"e604","DOI":"10.1161\/cir.0000000000000477","volume":"135","author":"AN Raval","year":"2017","unstructured":"Raval AN, Cigarroa JE, Chung MK et al (2017) Management of Patients on non-vitamin K antagonist Oral anticoagulants in the acute care and Periprocedural setting: a scientific statement from the American Heart Association. Circulation 135(10):e604\u2013e633. https:\/\/doi.org\/10.1161\/cir.0000000000000477","journal-title":"Circulation"},{"issue":"1","key":"786_CR61","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/bjh.18189","volume":"198","author":"R Riat","year":"2022","unstructured":"Riat R, Gomez K (2022) Addendum to guidelines on the investigation and management of venous thrombosis at unusual sites (Br. J. Haematol. 2012;159:28\u201338): use of direct Oral anticoagulants. Br J Haematol 198(1):46\u201349. https:\/\/doi.org\/10.1111\/bjh.18189","journal-title":"Br J Haematol"},{"issue":"2","key":"786_CR62","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/rth2.12480","volume":"5","author":"N Riva","year":"2021","unstructured":"Riva N, Ageno W (2021) Direct oral anticoagulants for unusual-site venous thromboembolism. Res Pract Thromb Haemost 5(2):265\u2013277. https:\/\/doi.org\/10.1002\/rth2.12480","journal-title":"Res Pract Thromb Haemost"},{"issue":"8","key":"786_CR63","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.04.004","volume":"27","author":"DK Rose","year":"2018","unstructured":"Rose DK, Bar B (2018) Direct Oral anticoagulant agents: pharmacologic profile, indications, coagulation monitoring, and reversal agents. J Stroke Cerebrovasc Dis 27(8):2049\u20132058. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2018.04.004","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"9921","key":"786_CR64","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/s0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383(9921):955\u2013962. https:\/\/doi.org\/10.1016\/s0140-6736(13)62343-0","journal-title":"Lancet"},{"key":"786_CR65","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.thromres.2020.06.044","volume":"195","author":"JR Shaw","year":"2020","unstructured":"Shaw JR, Carrier M, Dowlatshahi D, Chakraborty S, Tokessy M, Buyukdere H, Castellucci LA (2020) Activated prothrombin complex concentrates for direct oral anticoagulant-associated bleeding or urgent surgery: hemostatic and thrombotic outcomes. Thromb Res 195:21\u201328. https:\/\/doi.org\/10.1016\/j.thromres.2020.06.044","journal-title":"Thromb Res"},{"issue":"3","key":"786_CR66","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jtha.2022.11.029","volume":"21","author":"JR Shaw","year":"2023","unstructured":"Shaw JR, Castellucci LA, Siegal D, Carrier M (2023) DOAC-associated bleeding, hemostatic strategies, and thrombin generation assays \u2013 a review of the literature. J Thromb Haemost 21(3):433\u2013452. https:\/\/doi.org\/10.1016\/j.jtha.2022.11.029","journal-title":"J Thromb Haemost"},{"issue":"25","key":"786_CR67","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","volume":"373","author":"DM Siegal","year":"2015","unstructured":"Siegal DM, Curnutte JT, Connolly SJ et al (2015) Andexanet Alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 373(25):2413\u20132424. https:\/\/doi.org\/10.1056\/NEJMoa1510991","journal-title":"N Engl J Med"},{"issue":"9","key":"786_CR68","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s40266-024-01138-5","volume":"41","author":"JR Spruit","year":"2024","unstructured":"Spruit JR, de Vries TAC, Hemels MEW, Pisters R, de Groot JR, Jansen R (2024) Direct Oral anticoagulants in older and frail patients with atrial fibrillation: a decade of experience. Drugs Aging 41(9):725\u2013740. https:\/\/doi.org\/10.1007\/s40266-024-01138-5","journal-title":"Drugs Aging"},{"issue":"10","key":"786_CR69","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","volume":"23","author":"J Steffel","year":"2021","unstructured":"Steffel J, Collins R, Antz M et al (2021) 2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist Oral anticoagulants in patients with atrial fibrillation. Europace 23(10):1612\u20131676. https:\/\/doi.org\/10.1093\/europace\/euab065","journal-title":"Europace"},{"issue":"1","key":"786_CR70","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1055\/s-0043-1776989","volume":"8","author":"R Talerico","year":"2024","unstructured":"Talerico R, Pola R, Klok FA, Huisman MV (2024) Direct-acting Oral anticoagulants in patients at extremes of body weight: a review of pharmacological considerations and clinical implications. TH Open 8(1):e31\u2013e41. https:\/\/doi.org\/10.1055\/s-0043-1776989","journal-title":"TH Open"},{"issue":"10","key":"786_CR71","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","volume":"78","author":"MG Tektonidou","year":"2019","unstructured":"Tektonidou MG, Andreoli L, Limper M et al (2019) EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 78(10):1296\u20131304. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215213","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"786_CR72","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1093\/ehjcvp\/pvac036","volume":"8","author":"R Tripathi","year":"2022","unstructured":"Tripathi R, Morales J, Lee V et al (2022) Antithrombotic drug removal from whole blood using Haemoadsorption with a porous polymer bead sorbent. Eur Heart J Cardiovasc Pharmacother 8(8):847\u2013856. https:\/\/doi.org\/10.1093\/ehjcvp\/pvac036","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"3","key":"786_CR73","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/jth.12485","volume":"12","author":"T van der Hulle","year":"2014","unstructured":"van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV (2014) Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 12(3):320\u2013328. https:\/\/doi.org\/10.1111\/jth.12485","journal-title":"J Thromb Haemost"},{"issue":"7","key":"786_CR74","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1111\/jth.14156","volume":"16","author":"L Vasanthamohan","year":"2018","unstructured":"Vasanthamohan L, Boonyawat K, Chai-Adisaksopha C, Crowther M (2018) Reduced-dose direct oral anticoagulants in the extended treatment of venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 16(7):1288\u20131295. https:\/\/doi.org\/10.1111\/jth.14156","journal-title":"J Thromb Haemost"},{"issue":"1","key":"786_CR75","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/s41467-017-00647-9","volume":"8","author":"D Verhoef","year":"2017","unstructured":"Verhoef D, Visscher KM, Vosmeer CR, Cheung KL, Reitsma PH, Geerke DP, Bos MA (2017) Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors. Nat Commun 8(1):528. https:\/\/doi.org\/10.1038\/s41467-017-00647-9","journal-title":"Nat Commun"},{"issue":"2","key":"786_CR76","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.ahj.2007.10.004","volume":"155","author":"N Wanahita","year":"2008","unstructured":"Wanahita N, Messerli FH, Bangalore S, Gami AS, Somers VK, Steinberg JS (2008) Atrial fibrillation and obesity--results of a meta-analysis. Am Heart J 155(2):310\u2013315. https:\/\/doi.org\/10.1016\/j.ahj.2007.10.004","journal-title":"Am Heart J"},{"issue":"9","key":"786_CR77","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1182\/blood-2017-04-778993","volume":"130","author":"TE Warkentin","year":"2017","unstructured":"Warkentin TE, Pai M, Linkins LA (2017) Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review. Blood 130(9):1104\u20131113. https:\/\/doi.org\/10.1182\/blood-2017-04-778993","journal-title":"Blood"},{"issue":"6","key":"786_CR78","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1182\/bloodadvances.2021005808","volume":"6","author":"SC Woller","year":"2022","unstructured":"Woller SC, Stevens SM, Kaplan D et al (2022) Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial. Blood Adv 6(6):1661\u20131670. https:\/\/doi.org\/10.1182\/bloodadvances.2021005808","journal-title":"Blood Adv"},{"issue":"20","key":"786_CR79","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/jco.2018.78.8034","volume":"36","author":"AM Young","year":"2018","unstructured":"Young AM, Marshall A, Thirlwall J et al (2018) Comparison of an Oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 36(20):2017\u20132023. https:\/\/doi.org\/10.1200\/jco.2018.78.8034","journal-title":"J Clin Oncol"},{"issue":"10","key":"786_CR80","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.jacc.2019.12.060","volume":"75","author":"M Zeitouni","year":"2020","unstructured":"Zeitouni M, Giczewska A, Lopes RD et al (2020) Clinical and pharmacological effects of Apixaban dose adjustment in the ARISTOTLE trial. J Am Coll Cardiol 75(10):1145\u20131155. https:\/\/doi.org\/10.1016\/j.jacc.2019.12.060","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"786_CR81","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1111\/jth.14935","volume":"18","author":"S Zuily","year":"2020","unstructured":"Zuily S, Cohen H, Isenberg D et al (2020) Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on thrombosis and Haemostasis. J Thromb Haemost 18(9):2126\u20132137. https:\/\/doi.org\/10.1111\/jth.14935","journal-title":"J Thromb Haemost"}],"container-title":["Handbook of Experimental Pharmacology","Antithrombotic and Antiplatelet Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2025_786","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T18:42:49Z","timestamp":1777056169000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/164_2025_786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9783032228994","9783032229007"],"references-count":81,"URL":"https:\/\/doi.org\/10.1007\/164_2025_786","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"30 December 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}